IMMP Immutep
- 2.030
- +0.040+2.01%
Immutep News
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)
Baird Maintains Immutep(IMMP.US) With Buy Rating, Raises Target Price to $7
Immutep Analyst Ratings
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
Capital One Financial Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Immutep on Promising Efti Outlook Despite Mixed Study Interpretations
Immutep Ltd (PRRUF) Gets a Buy From Bell Potter
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Immutep Ltd (OtherPRRUF)
Immutep Price Target Cut 6.7% to A$0.70/Share by Bell Potter
Capital One Financial Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $8
Capital One Financial Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $8
Immutep's Innovative LAG-3 Focused Therapies Poised to Transform Advanced Cancer Treatments: A Buy Rating Overview
Immutep Ltd (PRRUF) Gets a Buy From Canaccord Genuity
Jefferies Remains a Buy on Immutep Ltd (PRRUF)
Analysts' Top Healthcare Picks: UnitedHealth (UNH), Immutep (IMMP)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)
Buy Rating Affirmed: Immutep's Efti Shows Promising Results in HNSCC Therapy
Buy Rating Affirmed for Immutep Limited Amid Promising Efti Clinical Results in Oncology
Immutep Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF) and Redcare Pharmacy (GB:0RJT)
Analysis
Price Target
No Data
No Data